5 min listen
Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
ratings:
Length:
56 minutes
Released:
Mar 20, 2023
Format:
Podcast episode
Description
On the surface, the merger of Medsenic (a developer of arsenic salt formulations for therapeutic application in inflammatory conditions) and Bone Therapeutics (which develops allogeneic cell therapies for complicated bone fractures) doesn't look obviously synergistic. But Francois Rieger, Ph.D. says that on the scientific level, it's a perfect union, and the veteran biotech founder says the business should always follow the science. The union of the two companies formed BioSenic, which Dr. Regier now serves as CEO. On this week's episode of the Business of Biotech, Dr. Regier shows us the good, the bad, and the ugly of the merger process and shares his philosophy on letting science lead the way, regardless of the analysts' takes. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
Released:
Mar 20, 2023
Format:
Podcast episode
Titles in the series (100)
Business Of Biotech Trailer by Business Of Biotech